Compare IPI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPI | CLLS |
|---|---|---|
| Founded | 2000 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 419.8M | 394.4M |
| IPO Year | 2007 | 2014 |
| Metric | IPI | CLLS |
|---|---|---|
| Price | $31.13 | $1.08 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $36.50 | $4.83 |
| AVG Volume (30 Days) | ★ 163.8K | 94.7K |
| Earning Date | 11-03-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.14 | N/A |
| EPS | ★ 1.73 | N/A |
| Revenue | ★ $298,328,000.00 | N/A |
| Revenue This Year | $13.45 | N/A |
| Revenue Next Year | N/A | $10.70 |
| P/E Ratio | $18.17 | ★ N/A |
| Revenue Growth | ★ 17.13 | N/A |
| 52 Week Low | $22.55 | $0.88 |
| 52 Week High | $50.34 | $5.45 |
| Indicator | IPI | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 36.96 | 36.03 |
| Support Level | $30.36 | $0.88 |
| Resistance Level | $36.20 | $2.99 |
| Average True Range (ATR) | 1.06 | 0.10 |
| MACD | 0.13 | 0.06 |
| Stochastic Oscillator | 29.96 | 39.88 |
Intrepid Potash Inc produces and sells potash and potash byproducts in three main product segments: Potash, Trio, and Oilfield Solutions. The Potash segment produces and sells potash to the agricultural industry as a fertilizer input, the industrial market as a component of oil and gas drilling fluid, and the animal feed market as a nutrient supplement. The Trio segment produces and sells specialty fertilizer that consists of potassium, sulfate, and magnesium and is mined from langbeinite ore. The oilfield solutions segment offers water, high-speed potassium chloride mixing services, saltwater disposal services, and trucking services. The vast majority of revenue is generated in the United States, where the firm's production facilities are located.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.